Shire Announces European Approval of VPRIV (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
Advertisement
Shire plc announced that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease. VPRIV has been authorized as an orphan medicine through the Centralised Procedure, making it available in 30 countries acrossEurope.
This approval was based on data from Shire's velaglucerase alfa clinical development programme which represents the largest and most comprehensive clinical data set supporting registration for an ERT for type 1 Gaucher disease. In total, over 100 Gaucher patients at 24 sites in 10 countries around the world participated in the clinical studies, all of which met their primary endpoints.
AcrossEurope, hundreds of type 1 Gaucher patients have been receiving velaglucerase alfa through early access programmes, developed in partnership with national authorities, Gaucher expert physicians and patient associations. Globally there are over 850 patients on velaglucerase alfa and demand continues to be strong. As a result, Shire has implemented a program to carefully monitor demand and manage requests from physicians and patients in order to ensure long-term, uninterrupted treatment with VPRIV.
"The Marketing Authorisation for VPRIV in the EU is an important milestone for Shire," said Sylvie Grégoire, President, Shire Human Genetic Therapies. "Our efforts to accelerate our manufacturing, clinical and regulatory timelines have resulted in VPRIV's approval in Europe and the US months ahead of schedule."
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Bovine_spongiform_encephalopathy
How to achieve and maintain pharmaceutical compliance - Pharmaceutical Compliance Guide
PerkinElmer announces third quarter results - GAAP Revenue of $548 million versus $563 million in the comparable prior period
Category:Cardiac_surgery
Sigma-Aldrich and Sangamo BioSciences Announce Alliance to Develop Zinc Finger-Based Laboratory Research Reagents
ABB Robotics and Mettler-Toledo join forces to accelerate global adoption of flexible lab automation - Companies will redefining the limits of robotics in laboratories to accelerate innovation and address labor shortages
Merck Looks Ahead to the Future
Tracking Down Genetic Influences on Brain Disorders
Brain stent offers alternative to shunt for fixing potentially blinding vein narrowing - Pseudotumor cerebri condition marked by excessive pressure in skull, most common in obese, premenopausal women between the ages of 18 and 40